Literature DB >> 21905166

Comprehensive mutation analysis (20 families) of the choroideremia gene reveals a missense variant that prevents the binding of REP1 with Rab geranylgeranyl transferase.

Gabriella Esposito1, Francesca De Falco, Nadia Tinto, Francesco Testa, Luigi Vitagliano, Igor Cristian Maria Tandurella, Lucio Iannone, Settimio Rossi, Ernesto Rinaldi, Francesca Simonelli, Adriana Zagari, Francesco Salvatore.   

Abstract

Choroideremia (CHM), an X-linked degeneration of the retinal pigmented epithelium (RPE), photoreceptors, and choroid, ultimately leads to blindness. It is caused by loss-of-function of the CHM gene product, the Rab escort protein 1 (REP1) that is involved, together with its homologue REP2, in prenylation of Rab GTPases, key regulators of intracellular vesicular traffic. Here, we report the molecular characterization of 20 unrelated Italian families affected by CHM. We identified 19 different mutations, nine of which are new. In most cases, we analyzed the effect of the mutations at the mRNA level. Furthermore, we demonstrated, by in vitro trancription/translation assays, that the mutated mRNAs produced truncated proteins in all cases but one. In fact, we also identified a novel REP1 missense variant (c.1520A>G; p.H507R) associated to CHM. Thus far, only two other CHM-associated missense mutations have been identified, one of which was a splicing alteration. We investigated the impact of the p.H507R amino acid change on REP1 structure and function, thus providing the first experimental demonstration that correlates a missense mutation in CHM with a functional impairment of REP1. Overall, our results indicate that the REP1-Rab geranyl-geranyl transferase interaction and consequently REP1-mediated Rab prenylation is essential for RPE and photoreceptor function.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905166     DOI: 10.1002/humu.21591

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  23 in total

1.  Clinical utility gene card for: choroideremia.

Authors:  Mariya Moosajee; Simon C Ramsden; Graeme C M Black; Miguel C Seabra; Andrew R Webster
Journal:  Eur J Hum Genet       Date:  2013-08-21       Impact factor: 4.246

2.  Retinal dystrophy and subretinal drusenoid deposits in female choroideremia carriers.

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Ilaria Passerini; Simona Palchetti; Andrea Sodi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

3.  Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.

Authors:  Tomas S Aleman; Grace Han; Leona W Serrano; Nicole M Fuerst; Emily S Charlson; Denise J Pearson; Daniel C Chung; Anastasia Traband; Wei Pan; Gui-Shuang Ying; Jean Bennett; Albert M Maguire; Jessica I W Morgan
Journal:  Ophthalmology       Date:  2016-12-13       Impact factor: 12.079

4.  An overview of inborn errors of complex lipid biosynthesis and remodelling.

Authors:  Foudil Lamari; Fanny Mochel; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2014-09-20       Impact factor: 4.982

5.  CHOROIDEREMIA ASSOCIATED WITH A NOVEL SYNONYMOUS MUTATION IN GENE ENCODING REP-1.

Authors:  Jesse D Sengillo; Winston Lee; Mathieu F Bakhoum; Galaxy Y Cho; John P-W Chiang; Stephen H Tsang
Journal:  Retin Cases Brief Rep       Date:  2018 Fall

Review 6.  Gene therapy for choroideremia using an adeno-associated viral (AAV) vector.

Authors:  Alun R Barnard; Markus Groppe; Robert E MacLaren
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-30       Impact factor: 6.915

7.  Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date.

Authors:  Vasiliki Kalatzis; Anne-Françoise Roux; Isabelle Meunier
Journal:  Mol Diagn Ther       Date:  2021-10-18       Impact factor: 4.074

8.  Optical coherence tomography (OCT) features of cystoid spaces in choroideremia (CHM).

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Dario Giorgio; Andrea Sodi; Ilaria Passerini; Giacomo Bacci; Sara Bargiacchi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-26       Impact factor: 3.117

9.  Analysis of a large choroideremia dataset does not suggest a preference for inclusion of certain genotypes in future trials of gene therapy.

Authors:  Paul R Freund; Yuri V Sergeev; Ian M MacDonald
Journal:  Mol Genet Genomic Med       Date:  2016-02-28       Impact factor: 2.183

10.  Pathogenic mechanisms and the prospect of gene therapy for choroideremia.

Authors:  Ioannis S Dimopoulos; Stephanie Chan; Robert E MacLaren; Ian M MacDonald
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-01       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.